Financing

The authors declare that there has been no financial support or commercial interest in carrying out this work.

Conflict of Interest

The authors have no conflict of interest to state.

References


Miriam Almirall,a, Eisa Docampo, Xavier Estivill, Joan Maymó

a Servicio de Reumatología, Hospital del Mar, Parc de Salut Mar, Universidad Autònoma de Barcelona, Barcelona, Spain
b Genomics and Disease Group, Centro de Regulación Genómica (CRG), Instituto Municipal de Investigación Médica (IMIM), Barcelona, Spain

*Corresponding author.
E-mail address: REU0802@parcdesalutmar.cat (M. Almirall).

Usefulness of Ultrasound in Jaccoud’s Arthropathy. A Case Report

La ecografía en la artrpatía de Jaccoud. A propósito de un caso

To the Editor,

Joint involvement is one of the initial manifestations in most patients with systemic lupus erythematosus (SLE); ranging from joint pain to severe deforming arthritis.1 Within the deforming types, non erosive forms, such as Raynaud’s phenomenon and subacute cutaneous lupus erythematosus lesions. She had positive antinuclear antibodies (1/1280), anti-dsDNA, anti-Sm, anti-RNP and anti-CCP (high titers); anemia of chronic diseases and complement consumption. From the onset of the disease she has been treated with hydroxychloroquine, methotrexate and prednisone.

knees and elbows; scarring alopecia; Raynaud’s phenomenon and subacute cutaneous lupus erythematosus lesions. She had positive antinuclear antibodies (1/1280), anti-dsDNA, anti-Sm, anti-RNP and anti-CCP (high titers); anemia of chronic diseases and complement consumption. From the onset of the disease she has been treated with hydroxychloroquine, methotrexate and prednisone.

Fig. 1. Left hand of the patient with Jaccoud’s arthropathy where ulnar deviation of the 5th finger and sawn neck deformity of fingers 2–5 is appreciated.

Table 1

<table>
<thead>
<tr>
<th>ISL</th>
<th>Total</th>
<th>N.p. HLA-B27+</th>
<th>N.p. HLA-CW6+</th>
<th>N.p. HLA-DR1+</th>
<th>N.p. HLA-DR4+</th>
<th>N.p. HLA-DR7+</th>
<th>LCE 3C-LCE 3B-del D+/&gt;D+</th>
<th>LCE 3C-LCE 3B-del D+/&gt;D–</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin psoriasis</td>
<td>7</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Alopezia areata</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Cutaneous lupus</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Eczema</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Hydradenitis</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Erythema multiforme</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>15</td>
<td>7</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>6</td>
<td>4</td>
<td>11</td>
</tr>
</tbody>
</table>

LCE 3B–LCE 3B del, deletion of the late cornified envelope; ISL, induced skin lesions; N.p., number of patients; +, positive; D+, deleted; D–, non-deleted.

Currently, she is painless and has no reducible deformity of the hands, bilaterally, with a positive score (more than 5 points) for JA in the index proposed by Spronk et al., with predominating “gooseneck” deformities, evident ulnar deviation in some fingers and unilateral thumb Z’ deformity (Fig. 1). Despite being asymptomatic, C-REACTIVE protein (CRP) and erythrocyte sedimentation rate remained persistently positive, so an ultrasound of the wrists and hands was requested, after ruling out infections or other concurrent processes.

Synovial hypertrophy was observed in the radiocarpal and midcarpal joints bilaterally, according to the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT). It is described as an abnormal non-movable, intraarticular hypoechoic tissue, poorly compressible, 2nd stage, because it reached the top of the periarticular bone and did not extend to the diaphysis. The power Doppler signal was 2+ as confluent vascular signals were observed in the synovial area. Flexor tenosynovitis was also shown on the wrist, corresponding to a hypoechoic thickening of the synovial sheaths of the tendons with bilateral pathological Doppler (Fig. 2) signal corresponding to an increase of normal vascularization. Similarly, tenosynovitis was seen in all finger flexors with no evidence of bone erosions.

JA is a chronic deforming joint affection, associated with different diseases, which usually affects the metacarpophalangeal and proximal interphalangeal joints, wrists and knees. It leads to deformities that mimic rheumatoid arthritis (RA), predominantly dislocations, although with little pain and little functional impairment. Alterations are reducible and not the typical radiographic erosions seen in RA, even in patients with longstanding MR studied disease.

We hypothesize that tenosynovitis is a typical primary lesion and deformities result from the involvement of ligaments and tendons, rather than an erosive arthritis with pannus formation, as in RA.

In our patient, antiphospholipid antibodies were negative, contrary to the previously suggested association and she showed no renal involvement. There is a negative association between JA and kidney damage, despite the prevalence of anti-dsDNA antibody, suggesting a better prognosis in these patients.

The acute phase reactants and ultrasound abnormalities point to sustained synovial inflammation, consistent with previous publications in which higher CRP levels were observed in patients with JA compared with patients without it, despite a similar clinical situation and treatment.

We agree with other groups, on the importance and value of ultrasonography in patients with SLE although it is still not validated as an imaging technique for the assessment of lupus. In our case, it allowed us to detect elementary lesions suggestive of active inflammation, although the patient remained clinically asymptomatic. These alterations detected by ultrasound show, with great probability, subclinical tendon involvement due to the disease, similar to what has been suggested in other studies in patients with lupus, but without reference to JA. Nevertheless, more studies are needed to assess the need for a screening ultrasound or other imaging techniques in all patients with JA, or only those who remain with elevated acute phase reactants, looking for signs of inflammatory activity.

References

Rheumatoid Arthritis, a New Focus on Cardiovascular Risk

Artritis reumatoide, un nuevo enfoque del riesgo cardiovascular

Dear Editor,

Patients with rheumatoid arthritis (RA) have a greater prevalence of traditional risk factors and 68% more risk of developing a myocardial infarction1 than the general population, with this risk persisting even when the analysis is adjusted for traditional coronary risk factors.2,3 EULAR2 recommendations for the evaluation of cardiovascular risk in subjects with RA propose the application of risk evaluation methods such as, for example, the Framingham type. On the other hand, EULAR recommends special attention to subjects with long-standing RA (over 10 years), rheumatoid factor or anti-CCP antibody positivity as well as those with extra articular manifestations.3

Rheumatologists, in their daily clinical practice, must perform different indices: diagnostic, classification, disease activity, radiological progression, risk for fracture due to frailty (FRAX and others), patient quality of life, etc., to which we add the evaluation of coronary risk.

The 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines4 were recently published, which propose “extensive and consistent” evidence on the benefit of the use of statins in order to reduce the cardiovascular risk in subjects with LDLC over 70 mg/dL. Four groups of patients are identified in subjects who would benefit from the use of statins: (1) subjects with clinical cardiovascular disease; (2) subjects with LDLC ≥190 mg/dL; (3) diabetes between 40 and 75 years of age with LDLC between 70 and 189 mg/dL and no clinical cardiovascular disease, and (4) subjects with no clinical cardiovascular disease or diabetes, with LDLC between 70 and 189 mg/dL and a 10 year estimated risk of ≥7.5%.4

Because RA has a cardiovascular risk similar to diabetes mellitus,5 that the use of statins provide a modest but significant anti-inflammatory effect,6 and that the use of anti-inflammatory drugs (coxibs or non-coxibs) is associated to a greater coronary risk,7 we propose that subjects with RA and no clinical cardiovascular disease, with LDLC between 70 and 189 mg/dL and no upper limit for age be considered in group 3 of the four above-mentioned groups, which implies the use of statins in “moderate intensity”8 for most of the patients with RA; however, in subjects with long-standing RA who are rheumatoid factor/anti-CCP positive or have extra articular manifestations who comply with two or more of these criteria, the clinician might consider the use of “high intensity” statin treatment.8 These recommendations might be extended to subjects with spondyloarthritis, including psoriatic arthritis.8

The use of statins modifies the plasma lipid profile and the cardiovascular risk of subjects with inflammatory arthritis in a similar way than in patients without inflammatory arthropathy and this reduction of extended to RA, spondylitis and psoriatic arthritis9; even in subjects with RA who are using statins, the interruption in treatment is associated to an increase in the risk of cardiovascular mortality.10

In spite of the benefits in cardiovascular risk that, in our judgment, would be provided by statins in subjects with inflammatory arthritides, the clinician must always take into account the possibility of myopathy and especially liver toxicity that may occur in subjects who frequently take other hepatotoxic drugs.

In conclusion, we recommend that all patients with inflammatory arthritis, especially RA, over 40 years of age, with LDLC between 70 and 189 mg/dL and no cardiovascular disease receive statins at a moderate dose and those patients with a particularly high risk (two or more of these conditions: long-standing RA, rheumatoid factor/anti-CCP positivity, extra articular manifestations) receive statins in a high intensity regimen.

References

8. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondyloarthopathies, particularly...